| Year |
Citation |
Score |
| 2023 |
Udumula MP, Singh H, Rashid F, Poisson L, Tiwari N, Dimitrova I, Hijaz M, Gogoi R, Swenor M, Munkarah A, Giri S, Rattan R. Intermittent fasting induced ketogenesis inhibits mouse epithelial ovarian cancer by promoting antitumor T cell response. Iscience. 26: 107839. PMID 37822507 DOI: 10.1016/j.isci.2023.107839 |
0.344 |
|
| 2023 |
Udumula MP, Singh H, Faraz R, Poisson L, Tiwari N, Dimitrova I, Hijaz M, Gogoi R, Swenor M, Munkarah A, Giri S, Rattan R. Intermittent Fasting induced ketogenesis inhibits mouse epithelial ovarian tumors by promoting anti-tumor T cell response. Biorxiv : the Preprint Server For Biology. PMID 36945428 DOI: 10.1101/2023.03.08.531740 |
0.305 |
|
| 2022 |
Udumula MP, Poisson LM, Dutta I, Tiwari N, Kim S, Chinna-Shankar J, Allo G, Sakr S, Hijaz M, Munkarah AR, Giri S, Rattan R. Divergent Metabolic Effects of Metformin Merge to Enhance Eicosapentaenoic Acid Metabolism and Inhibit Ovarian Cancer In Vivo. Cancers. 14. PMID 35326656 DOI: 10.3390/cancers14061504 |
0.35 |
|
| 2021 |
Wahid M, Dar SA, Jawed A, Mandal RK, Akhter N, Khan S, Khan F, Jogiah S, Rai AK, Rattan R. Microbes in Gynecologic Cancers: Causes or Consequences and Therapeutic Potential. Seminars in Cancer Biology. PMID 34302959 DOI: 10.1016/j.semcancer.2021.07.013 |
0.342 |
|
| 2021 |
Udumula MP, Sakr S, Dar S, Alvero AB, Ali-Fehmi R, Abdulfatah E, Li J, Jiang J, Tang A, Buekers T, Morris R, Munkarah A, Giri S, Rattan R. Ovarian Cancer modulates the immunosuppressive function of CD11bGr1 myeloid cells via glutamine metabolism. Molecular Metabolism. 101272. PMID 34144215 DOI: 10.1016/j.molmet.2021.101272 |
0.37 |
|
| 2020 |
Xia H, Li S, Li X, Wang W, Bian Y, Wei S, Grove S, Wang W, Vatan L, Liu JR, McLean K, Rattan R, Munkarah AR, Guan JL, Kryczek I, et al. Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. Jci Insight. PMID 32780724 DOI: 10.1172/Jci.Insight.141115 |
0.489 |
|
| 2020 |
Raja V, Giri S, Hamid S, Buekers T, Munkarah A, Rattan R. Abstract A69: Role of mitochondrial-STAT3 in promoting chemoresistance by modulating the energy metabolism in ovarian cancer Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-A69 |
0.496 |
|
| 2020 |
Udumula M, Dimitrova I, Sakr S, Buekers T, Giri S, Rattan R. Omega-3 lipid metabolites as mediators of metformin’s anti-proliferative effect in ovarian cancer Gynecologic Oncology. 159: 124. DOI: 10.1016/j.ygyno.2020.05.148 |
0.322 |
|
| 2019 |
Raja V, Giri S, Hamid S, Munkarah AR, Rattan R. Abstract GMM-049: STAT3 PROMOTES OVARIAN CANCER GROWTH AND DRUG RESISTANCE BY MODULATING THE ENERGY METABOLISM Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Gmm-049 |
0.522 |
|
| 2019 |
Rattan R, Buekers TE, Raja V, Hijaz M, Hanna RK, Hamid S, Giri S, Munkarah AR. Role of MCP-1 in promoting adiposity-driven ovarian cancer Gynecologic Oncology. 154: 95. DOI: 10.1016/J.Ygyno.2019.04.223 |
0.444 |
|
| 2019 |
Rattan R, Raja V, Buekers TE, Hamid S, Elshaikh MA, Giri S, Munkarah AR. STAT3 promotes ovarian cancer growth and chemoresistance by modulating its energy metabolism Gynecologic Oncology. 154: 94-95. DOI: 10.1016/J.Ygyno.2019.04.222 |
0.421 |
|
| 2019 |
Hijaz M, Raja V, Sakr S, Buekers TE, Morris RT, Giri S, Munkarah AR, Rattan R. The contribution of adipocyte reservoirs towards ovarian cancer growth in time and site-specific manner Gynecologic Oncology. 154: 67-68. DOI: 10.1016/J.Ygyno.2019.04.160 |
0.395 |
|
| 2018 |
Sakr S, Dar S, Giri S, Munkarah A, Rattan R. Abstract B32: Myeloid-derived suppressor cell depletion augments antitumor activity in ovarian cancer Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B32 |
0.478 |
|
| 2018 |
Rattan R, Sakr S, Quiles R, Morris R, Buekers T, Munkarah A, Giri S. Abstract 4735: Role of myeloid derived suppressor cells in promoting ovarian cancer Cancer Research. 78: 4735-4735. DOI: 10.1158/1538-7445.Am2018-4735 |
0.51 |
|
| 2018 |
Sakr S, Munkarah AR, Buekers TE, Morris RT, Giri S, Rattan R. Omega-3 lipid metabolites inhibit the growth of ovarian cancer cells Gynecologic Oncology. 149: 69. DOI: 10.1016/J.Ygyno.2018.04.157 |
0.461 |
|
| 2018 |
Sakr S, Munkarah AR, Morris RT, Buekers TE, Giri S, Rattan R. Combined PD1 blockade and depletion of myeloid derived suppressor cells produces a synergistic antitumor effect in a murine model of ovarian cancer Gynecologic Oncology. 149: 55. DOI: 10.1016/J.Ygyno.2018.04.121 |
0.401 |
|
| 2018 |
Rattan R, Raja V, Rasool N, Elshaikh MA, Munkarah AR, Giri S. STAT3 modulates the energy metabolism of ovarian cancer cells Gynecologic Oncology. 149: 48. DOI: 10.1016/J.Ygyno.2018.04.104 |
0.457 |
|
| 2018 |
Rattan R, Sakr S, Ali-Fehmi R, Abdulfatah E, Hanna RK, Giri S, Munkarah AR. S-nitrosoglutathione, a physiologic nitric oxide carrier, reduces immunosupression in ovarian cancer Gynecologic Oncology. 149: 47. DOI: 10.1016/J.Ygyno.2018.04.102 |
0.384 |
|
| 2017 |
Xia H, Wang W, Crespo J, Kryczek I, Li W, Wei S, Bian Z, Maj T, He M, Liu RJ, He Y, Rattan R, Munkarah A, Guan JL, Zou W. Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity. Science Immunology. 2. PMID 29150439 DOI: 10.1126/Sciimmunol.Aan4631 |
0.409 |
|
| 2017 |
Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, Giri S, Munkarah A, Rattan R. Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells. Scientific Reports. 7: 8760. PMID 28821788 DOI: 10.1038/S41598-017-09206-0 |
0.507 |
|
| 2017 |
Mert I, Chhina J, Allo G, Dai J, Seward S, Carey MS, Llaurado M, Giri S, Rattan R, Munkarah AR. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Gynecologic Oncology. PMID 28545687 DOI: 10.1016/J.Ygyno.2017.05.019 |
0.469 |
|
| 2017 |
Naman CB, Rattan R, Nikoulina SE, Lee J, Miller BW, Moss NA, Armstrong L, Boudreau PD, Debonsi HM, Valeriote FA, Dorrestein PC, Gerwick WH. Integrating Molecular Networking and Biological Assays To Target the Isolation of a Cytotoxic Cyclic Octapeptide, Samoamide A, from an American Samoan Marine Cyanobacterium. Journal of Natural Products. PMID 28055219 DOI: 10.1021/Acs.Jnatprod.6B00907 |
0.353 |
|
| 2017 |
Rattan R, Dar S, Rasool N, Ali-Fehmi R, Giri S, Munkarah AR. Depletion of immunosuppressive myeloid-derived suppressor cells impedes ovarian cancer growth Gynecologic Oncology. 145: 213-214. DOI: 10.1016/J.Ygyno.2017.03.491 |
0.478 |
|
| 2017 |
Uddin MH, Buekers TE, Elshaikh MA, Giri S, Munkarah AR, Rattan R. Differential effects of saturated and unsaturated fatty acids on ovarian cancer growth Gynecologic Oncology. 145: 210. DOI: 10.1016/J.Ygyno.2017.03.483 |
0.385 |
|
| 2017 |
Hijaz M, Rasool N, Munkarah AR, Rattan R. Weighing your risks: Obesity and ovarian cancer Gynecologic Oncology. 145: 202. DOI: 10.1016/J.Ygyno.2017.03.465 |
0.339 |
|
| 2017 |
Rattan R, Buekers TE, Chhina J, Uddin MH, Giri S, Munkarah AR. Cisplatin exposure causes metabolic stress and adaptation in ovarian cancer cells Gynecologic Oncology. 145: 110. DOI: 10.1016/J.Ygyno.2017.03.260 |
0.409 |
|
| 2016 |
Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Gynecologic Oncology. PMID 27282964 DOI: 10.1016/J.Ygyno.2016.06.005 |
0.504 |
|
| 2016 |
Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, ... ... Rattan R, et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell. PMID 27133165 DOI: 10.1016/J.Cell.2016.04.009 |
0.437 |
|
| 2016 |
Rana S, Blowers EC, Tebbe C, Contreras JI, Radhakrishnan P, Kizhake S, Zhou T, Rajule RN, Arnst J, Munkarah AR, Rattan R, Natarajan A. Isatin derived spirocyclic analogs with α-methylene-γ-butyrolactone as anticancer agents: A structure activity rela-tionship study. Journal of Medicinal Chemistry. PMID 27077228 DOI: 10.1021/Acs.Jmedchem.6B00400 |
0.415 |
|
| 2016 |
Munkarah A, Mert I, Chhina J, Hamid S, Poisson L, Hensley-Alford S, Giri S, Rattan R. Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence. Gynecologic Oncology. 141: 72-9. PMID 27016232 DOI: 10.1016/J.Ygyno.2016.02.026 |
0.391 |
|
| 2016 |
Hijaz M, Das S, Mert I, Gupta A, Al-Wahab Z, Tebbe C, Dar S, Chhina J, Giri S, Munkarah A, Seal S, Rattan R. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer. Bmc Cancer. 16: 220. PMID 26979107 DOI: 10.1186/S12885-016-2206-4 |
0.499 |
|
| 2016 |
Munkarah A, Hamid S, Chhina J, Mert I, Jackson L, Hensley-Alford S, Chitale D, Giri S, Rattan R. Abstract A81: Targeting of free fatty acid signaling in ovarian cancer may serve as a potential therapeutic approach. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A81 |
0.514 |
|
| 2016 |
Munkarah A, Poisson L, Kim S, Chhina J, Giri S, Rattan R. Abstract 11: Metformin exerts differential metabolic effects in ovarian cancer cell lines Cancer Research. 76: 11-11. DOI: 10.1158/1538-7445.Am2016-11 |
0.486 |
|
| 2016 |
Taylor M, Mert I, Hijaz M, Chhina J, Morris RT, Giri S, Rattan R, Munkarah AR. Effects of an olaparib and metformin combination on the AMPK and DNA-damage pathways in ovarian cancer Gynecologic Oncology. 141: 197-198. DOI: 10.1016/J.Ygyno.2016.04.510 |
0.382 |
|
| 2016 |
Hijaz M, Das S, Mert I, Chhina J, Tebbe C, Dar S, Seal S, Munkarah AR, Rattan R. Targeting ovarian cancer by folic acid conjugated nanoceria Gynecologic Oncology. 141: 184-185. DOI: 10.1016/J.Ygyno.2016.04.476 |
0.394 |
|
| 2016 |
Munkarah AR, Kim S, Buekers TE, Chhina J, Poisson L, Giri S, Rattan R. Metabolic effects of metformin treatment in ovarian cancer cell lines Gynecologic Oncology. 141: 168. DOI: 10.1016/J.Ygyno.2016.04.438 |
0.461 |
|
| 2016 |
Mert I, Munkarah AR, Hanna RK, Chhina J, Carey MS, Llaurado M, Rattan R. Is it time to repurpose metformin for the treatment of low-grade ovarian cancer? Gynecologic Oncology. 141: 55-56. DOI: 10.1016/J.Ygyno.2016.04.165 |
0.407 |
|
| 2015 |
Poisson LM, Suhail H, Singh J, Datta I, Denic A, Labuzek K, Hoda MN, Shankar A, Kumar A, Cerghet M, Elias S, Mohney RP, Rodriguez M, Rattan R, Mangalam AK, et al. Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. The Journal of Biological Chemistry. PMID 26546682 DOI: 10.1074/Jbc.M115.679068 |
0.314 |
|
| 2015 |
Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. Oncotarget. 6: 10908-23. PMID 25895126 DOI: 10.18632/Oncotarget.3434 |
0.42 |
|
| 2015 |
Poisson LM, Munkarah A, Madi H, Datta I, Hensley-Alford S, Tebbe C, Buekers T, Giri S, Rattan R. A metabolomic approach to identifying platinum resistance in ovarian cancer. Journal of Ovarian Research. 8: 13. PMID 25880539 DOI: 10.1186/S13048-015-0140-8 |
0.431 |
|
| 2015 |
Chhina J, Dar S, Deshpande M, Giri S, Munkarah A, Rattan R. Abstract POSTER-BIOL-1307: Bioenergetic adaptations in chemoresistant ovarian cancer cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1307 |
0.458 |
|
| 2015 |
Alford SH, Rattan R, Diaz M, Munkarah AR. Association of high-density lipoprotein cholesterol with ovarian cancer diagnosis Gynecologic Oncology. 137: 182. DOI: 10.1016/J.Ygyno.2015.01.458 |
0.331 |
|
| 2015 |
Madi HM, Al-Wahab Z, Poisson L, Burmeister C, Alford SH, Morris RT, Rattan R, Munkarah AR. Association of AMPK signaling pathway with tumor response to treatment in ovarian cancer Gynecologic Oncology. 137: 178. DOI: 10.1016/J.Ygyno.2015.01.447 |
0.399 |
|
| 2015 |
Rattan R, Chhina J, Dar S, Alford SH, Deshpande M, Rasool N, Giri S, Munkarah AR. Heterogeneity of energy dynamics in ovarian cancer cell lines Gynecologic Oncology. 137: 115. DOI: 10.1016/J.Ygyno.2015.01.286 |
0.418 |
|
| 2015 |
Hijaz M, Chhina J, Dar S, Tebbe C, Al-Wahab Z, Hanna RK, Rattan R, Munkarah AR. Synthetic lethality of PARP inhibitors and metformin in BRCA1 intact ovarian cancer Gynecologic Oncology. 137: 18. DOI: 10.1016/J.Ygyno.2015.01.043 |
0.44 |
|
| 2014 |
Al-Wahab Z, Tebbe C, Chhina J, Dar SA, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Dietary energy balance modulates ovarian cancer progression and metastasis. Oncotarget. 5: 6063-75. PMID 25026276 DOI: 10.18632/Oncotarget.2168 |
0.458 |
|
| 2014 |
Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, Munkarah AR, Rattan R. Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget. 5: 4746-64. PMID 24970804 DOI: 10.18632/Oncotarget.2012 |
0.526 |
|
| 2014 |
Giri S, Rattan R, Deshpande M, Maguire JL, Johnson Z, Graham RP, Shridhar V. Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer. Plos One. 9: e97897. PMID 24887420 DOI: 10.1371/Journal.Pone.0097897 |
0.52 |
|
| 2014 |
Al-Wahab Z, Tebbe C, Chhina J, Morris R, Giri S, Rattan R, Munkarah A. Effect of dietary modulation on ovarian cancer progression and metastasis Gynecologic Oncology. 133: 184. DOI: 10.1016/J.YGYNO.2014.03.488 |
0.326 |
|
| 2014 |
Al-Wahab Z, Tebbe C, Chhina J, Morris R, Giri S, Munkarah A, Rattan R. The inhibitory effects of metformin on ovarian cancer growth mimic those seen with caloric restriction Gynecologic Oncology. 133: 184. DOI: 10.1016/J.YGYNO.2014.03.487 |
0.325 |
|
| 2013 |
Giri S, Karakoti A, Graham RP, Maguire JL, Reilly CM, Seal S, Rattan R, Shridhar V. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. Plos One. 8: e54578. PMID 23382918 DOI: 10.1371/Journal.Pone.0054578 |
0.467 |
|
| 2013 |
Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W, Shridhar V. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer. 119: 555-62. PMID 23208739 DOI: 10.1002/cncr.27706 |
0.372 |
|
| 2013 |
Rattan R, Tebbe C, Chhina J, Sarigiannis K, Giri S, Munkarah A. Abstract B77: Targeting ovarian cancer promoting effects of adipocytes by metformin Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B77 |
0.536 |
|
| 2012 |
Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. Journal of Oncology. 2012: 928127. PMID 22701483 DOI: 10.1155/2012/928127 |
0.441 |
|
| 2011 |
Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (New York, N.Y.). 13: 483-91. PMID 21532889 DOI: 10.1593/Neo.11148 |
0.496 |
|
| 2011 |
Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, Ota T, Mariani A, Podratz KC, Chien J, Shridhar V. Expression and functional significance of HtrA1 loss in endometrial cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 427-36. PMID 21098697 DOI: 10.1158/1078-0432.Ccr-09-3069 |
0.408 |
|
| 2011 |
Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner Journal of Cellular and Molecular Medicine. 15: 166-178. PMID 19874425 DOI: 10.1111/J.1582-4934.2009.00954.X |
0.537 |
|
| 2010 |
Beleford D, Rattan R, Chien J, Shridhar V. High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines. The Journal of Biological Chemistry. 285: 12011-27. PMID 20154083 DOI: 10.1074/Jbc.M109.097790 |
0.435 |
|
| 2010 |
Beleford D, Liu Z, Rattan R, Quagliuolo L, Boccellino M, Baldi A, Maguire J, Staub J, Molina J, Shridhar V. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 398-409. PMID 20068077 DOI: 10.1158/1078-0432.Ccr-09-1677 |
0.353 |
|
| 2010 |
Rattan R, Narita K, Chien J, Maguire JL, Shridhar R, Giri S, Shridhar V. TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway. Oncogene. 29: 1362-73. PMID 19966855 DOI: 10.1038/Onc.2009.431 |
0.406 |
|
| 2010 |
Peedicayil A, Rattan R, He X, Kalli KR, Cliby WA, Chien J, Shridhar V. Abstract 3544: Assessment of chemo-response in cells derived from patients with malignant ascites Cancer Research. 70: 3544-3544. DOI: 10.1158/1538-7445.Am10-3544 |
0.412 |
|
| 2009 |
Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Research. 69: 4843-50. PMID 19487294 DOI: 10.1158/0008-5472.Can-08-3065 |
0.482 |
|
| 2009 |
Nath N, Khan M, Rattan R, Mangalam A, Makkar RS, de Meester C, Bertrand L, Singh I, Chen Y, Viollet B, Giri S. Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochemical and Biophysical Research Communications. 386: 16-20. PMID 19486896 DOI: 10.1016/J.Bbrc.2009.05.106 |
0.518 |
|
| 2009 |
Giri S, Rattan R, Karakoti A, Seal S, Shridhar V. Abstract C48: Antiangiogenic properties of rare earth nanoparticles: Implications in ovarian cancer Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C48 |
0.43 |
|
| 2009 |
Rattan R, Giri S, Hartmann LC, Shridhar V. Abstract C38: Metformin inhibits cancer cell growth in an AMP kinase‐independent and ‐dependent manner Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C38 |
0.521 |
|
| 2008 |
Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation Oncogene. 27: 7223-7234. PMID 18806825 DOI: 10.1038/Onc.2008.360 |
0.48 |
|
| 2008 |
Rattan R, Giri S, Singh I. Lovastatin induced cytokine-mediated inducible nitric oxide synthase (INOS) expression in brain transformed cell lines Journal of Neurochemistry. 81: 54-56. DOI: 10.1046/J.1471-4159.81.S1.18_8.X |
0.551 |
|
| 2006 |
Giri S, Rattan R, Haq E, Khan M, Yasmin R, Won JS, Key L, Singh AK, Singh I. AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutrition & Metabolism. 3: 31. PMID 16901342 DOI: 10.1186/1743-7075-3-31 |
0.497 |
|
| 2006 |
Giri S, Khan M, Rattan R, Singh I, Singh AK. Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death. Journal of Lipid Research. 47: 1478-92. PMID 16645197 DOI: 10.1194/Jlr.M600084-Jlr200 |
0.535 |
|
| 2006 |
Rattan R, Giri S, Singh AK, Singh I. Rho/ROCK pathway as a target of tumor therapy. Journal of Neuroscience Research. 83: 243-55. PMID 16385577 DOI: 10.1002/Jnr.20707 |
0.545 |
|
| 2005 |
Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. The Journal of Biological Chemistry. 280: 39582-93. PMID 16176927 DOI: 10.1074/Jbc.M507443200 |
0.603 |
|
| 2004 |
Giri S, Rattan R, Singh AK, Singh I. The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. Journal of Immunology (Baltimore, Md. : 1950). 173: 5196-208. PMID 15470065 DOI: 10.4049/Jimmunol.173.8.5196 |
0.512 |
|
| 2003 |
Rattan R, Giri S, Singh AK, Singh I. Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. Free Radical Biology & Medicine. 35: 1037-50. PMID 14572607 DOI: 10.1016/S0891-5849(03)00459-3 |
0.544 |
|
| 2002 |
Giri S, Jatana M, Rattan R, Won JS, Singh I, Singh AK. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 16: 661-72. PMID 11978730 DOI: 10.1096/Fj.01-0798Com |
0.519 |
|
| Show low-probability matches. |